{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:26:38Z","timestamp":1793366798612,"version":"4.5.0"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.intimp.2021.107398","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T16:28:18Z","timestamp":1612801698000},"page":"107398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review"],"prefix":"10.1016","volume":"93","author":[{"given":"Raghad D.","family":"Alamri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen A.","family":"Elmeligy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadeer A.","family":"Albalawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Alquayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaher S.","family":"Alsubhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7032-528X","authenticated-orcid":false,"given":"Sabah H.","family":"El-Ghaiesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2021.107398_b0005","unstructured":"Sanofi-aventis: ARAVA\u00ae Tablets (leflunomide) 10 mg, 20 mg, 100 mg http:\/\/products.sanofi.us\/arava\/Arava.html, June 2020. In. Edited by Aventis S, vol. LEF-FPLR-SL-FEB16: Sanofi Aventis, 2016, pp. 1\u201325."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0192-0561(85)90003-7","article-title":"Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity\u2013I. Disease modifying action on adjuvant arthritis of the rat","volume":"7","author":"Bartlett","year":"1985","journal-title":"Int. J. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107398_b0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0014-5793(93)81704-4","article-title":"Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide","volume":"334","author":"Mattar","year":"1993","journal-title":"FEBS Lett."},{"issue":"1 Pt 1","key":"10.1016\/j.intimp.2021.107398_b0020","first-page":"745","article-title":"Immunosuppressive effects of leflunomide in a cardiac allograft model","volume":"25","author":"Williams","year":"1993","journal-title":"Transpl. Proc."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2005.01152.x","article-title":"Concurrent antiviral and immunosuppressive activities of leflunomide in vivo","volume":"6","author":"Chong","year":"2006","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surgeons"},{"issue":"2","key":"10.1016\/j.intimp.2021.107398_b0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1399-3062.2006.00150.x","article-title":"Polyomavirus-associated nephropathy: update on antiviral strategies","volume":"8","author":"Josephson","year":"2006","journal-title":"Transplant Infect. Dis. Off. J. Transplant. Soc."},{"key":"10.1016\/j.intimp.2021.107398_b0035","unstructured":"Hannah AL: Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse. In.: https:\/\/ClinicalTrials.gov\/show\/NCT00003775, 2006."},{"key":"10.1016\/j.intimp.2021.107398_b0040","unstructured":"A.L.P. Hannah, SUGEN\u201c: SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme. In.: https:\/\/ClinicalTrials.gov\/show\/NCT00003293. June 2020, 2012."},{"issue":"4","key":"10.1016\/j.intimp.2021.107398_b0045","first-page":"800","article-title":"A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer","volume":"7","author":"Ko","year":"2001","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-2006-933412","article-title":"Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide","volume":"218","author":"Ehlert","year":"2006","journal-title":"Klin. Padiatr."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1399-3046.2009.01183.x","article-title":"Leflunomide therapy for BK virus allograft nephropathy in pediatric and young adult kidney transplant recipients","volume":"14","author":"Araya","year":"2010","journal-title":"Pediatr. Transplant."},{"issue":"4","key":"10.1016\/j.intimp.2021.107398_b0060","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1128\/JVI.01737-09","article-title":"Leflunomide inhibition of BK virus replication in renal tubular epithelial cells","volume":"84","author":"Bernhoff","year":"2010","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.intimp.2021.107398_b0065","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1432-2277.2007.00523.x","article-title":"Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation","volume":"20","author":"Faguer","year":"2007","journal-title":"Transplant Int. Off. J. Eur. Soc. Organ Transplant."},{"issue":"2","key":"10.1016\/j.intimp.2021.107398_b0070","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1111\/petr.12029","article-title":"Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation","volume":"17","author":"Jung","year":"2013","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.intimp.2021.107398_b0075","unstructured":"M. Millis, L. Perea, Leflunomide in Mild COVID-19 Patients. In.: https:\/\/ClinicalTrials.gov\/show\/NCT04361214, 2020."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.dld.2003.06.002","article-title":"Leflunomide-induced acute hepatitis","volume":"36","author":"Sevilla-Mantilla","year":"2004","journal-title":"Digest. Liver Dis. Off. J. Italian Soc. Gastroenterol. Italian Association Study Liver"},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0085","first-page":"9","article-title":"Severe hepatotoxicity in a rheumatoid arthritis patient switched from leflunomide to methotrexate","volume":"7","author":"Gupta","year":"2005","journal-title":"MedGenMed Medscape General Med."},{"issue":"5","key":"10.1016\/j.intimp.2021.107398_b0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00002018-200427050-00006","article-title":"Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity","volume":"27","author":"van Roon","year":"2004","journal-title":"Drug Saf."},{"issue":"7","key":"10.1016\/j.intimp.2021.107398_b0095","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1157\/13108810","article-title":"Acute hepatitis associated to leflunomide in a patient with rheumatoid arthritis","volume":"30","author":"Ch\u00e1vez-L\u00f3pez","year":"2007","journal-title":"Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.intimp.2021.107398_b0100","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.1780381111","article-title":"Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study","volume":"38","author":"Mladenovic","year":"1995","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.intimp.2021.107398_b0105","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1046\/j.1365-2125.1999.00095.x","article-title":"A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs","volume":"48","author":"Garcia Rodriguez","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2021.107398_b0115","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/art.11452","article-title":"Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients","volume":"49","author":"Siva","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.intimp.2021.107398_b0120","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1002\/1529-0131(200011)43:11<2609::AID-ANR32>3.0.CO;2-R","article-title":"Serious liver disease in a patient receiving methotrexate and leflunomide","volume":"43","author":"Weinblatt","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2021.107398_b0125","unstructured":"US-FDA: Highlights of Prescribing Information: Arava (leflunomide) In., 2015."},{"issue":"5","key":"10.1016\/j.intimp.2021.107398_b0130","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1055\/s-0031-1296204","article-title":"Risk of hepatotoxicity with add-on leflunomide in rheumatoid arthritis patients","volume":"61","author":"Gupta","year":"2011","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"10.1016\/j.intimp.2021.107398_b0135","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.athoracsur.2003.08.022","article-title":"Post-coronary artery bypass graft liver failure: a possible association with leflunomide","volume":"79","author":"Thomasset","year":"2005","journal-title":"Ann. Thoracic Surgery"},{"issue":"11","key":"10.1016\/j.intimp.2021.107398_b0140","first-page":"2657","article-title":"Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells","volume":"4","author":"Ghosh","year":"1998","journal-title":"Clinical Cancer Res. Off. J. American Assoc. Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2021.107398_b0145","first-page":"403","article-title":"Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents","volume":"14","author":"Ghosh","year":"1999","journal-title":"Anticancer Drug Des."},{"issue":"10","key":"10.1016\/j.intimp.2021.107398_b0150","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s10495-006-9439-7","article-title":"Low dose leflunomide activates PI3K\/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents","volume":"11","author":"Leger","year":"2006","journal-title":"Apoptosis Int. J. Programmed Cell Death"},{"issue":"24","key":"10.1016\/j.intimp.2021.107398_b0155","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.4161\/cc.6.24.5096","article-title":"Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases","volume":"6","author":"Uckun","year":"2007","journal-title":"Cell cycle (Georgetown, Tex)"},{"issue":"6","key":"10.1016\/j.intimp.2021.107398_b0160","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1593\/neo.10168","article-title":"Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention","volume":"12","author":"Hail","year":"2010","journal-title":"Neoplasia (New York, NY)"},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0165","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jss.2013.05.089","article-title":"Leflunomide suppresses growth in human medullary thyroid cancer cells","volume":"185","author":"Alhefdhi","year":"2013","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.intimp.2021.107398_b0170","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.biochi.2017.02.003","article-title":"Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells","volume":"135","author":"Mohamad Fairus","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.intimp.2021.107398_b0175","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2147\/DDDT.S252626","article-title":"Leflunomide inhibits proliferation and induces apoptosis via suppressing autophagy and PI3K\/Akt signaling pathway in human bladder cancer cells","volume":"14","author":"Cheng","year":"2020","journal-title":"Drug Des. Develop. Therapy"},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13058-020-01301-x","article-title":"Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer","volume":"22","author":"Humphries","year":"2020","journal-title":"Breast Cancer Res. BCR"},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0185","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1586\/14787210.5.1.105","article-title":"Antivirals for the treatment of polyomavirus BK replication","volume":"5","author":"Rinaldo","year":"2007","journal-title":"Expert Rev. Anti-infective Therapy"},{"issue":"24","key":"10.1016\/j.intimp.2021.107398_b0190","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2146\/ajhp160585","article-title":"Antiviral treatment of BK virus viremia after kidney transplantation","volume":"74","author":"Santeusanio","year":"2017","journal-title":"Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharmacists"},{"issue":"5","key":"10.1016\/j.intimp.2021.107398_b0195","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/jmv.25024","article-title":"Antiviral activity of A771726, the active metabolite of leflunomide, against Junin virus","volume":"90","author":"Sepulveda","year":"2018","journal-title":"J. Med. Virol."},{"issue":"10","key":"10.1016\/j.intimp.2021.107398_b0200","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1124\/dmd.31.10.1240","article-title":"In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes","volume":"31","author":"Kalgutkar","year":"2003","journal-title":"Drug Metabol. Disposit. Biolog. Fate Chem."},{"issue":"7","key":"10.1016\/j.intimp.2021.107398_b0205","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1021\/acs.jmedchem.6b00088","article-title":"Detection of in vitro metabolite formation of leflunomide: a fluorescence dynamics and electronic structure study","volume":"59","author":"Sharma","year":"2016","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.intimp.2021.107398_b0210","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/0885066615610108","article-title":"Use of a cholestyramine washout in a patient with septic shock on leflunomide therapy: a case report and review of the literature","volume":"31","author":"Laub","year":"2016","journal-title":"J. Intensive Care Med."},{"issue":"8","key":"10.1016\/j.intimp.2021.107398_b0215","first-page":"389","article-title":"Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy","volume":"15","author":"Wong","year":"2009","journal-title":"J. Clin. Rheumatol. Practical Rep. Rheumatic Musculoskeletal Dis."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0220","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/00007691-199502000-00014","article-title":"Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography","volume":"17","author":"Dias","year":"1995","journal-title":"Ther. Drug Monit."},{"issue":"5","key":"10.1016\/j.intimp.2021.107398_b0225","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/00007691-199510000-00004","article-title":"Blood distribution and single-dose pharmacokinetics of leflunomide","volume":"17","author":"Lucien","year":"1995","journal-title":"Ther. Drug Monit."},{"issue":"13","key":"10.1016\/j.intimp.2021.107398_b0230","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1021\/jm970039n","article-title":"A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug","volume":"40","author":"Bertolini","year":"1997","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2021.107398_b0235","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/187231207783221402","article-title":"In vitro metabolism of leflunomide by mouse and human liver microsomes","volume":"1","author":"Chan","year":"2007","journal-title":"Drug Metab. Lett."},{"issue":"1 Pt 1","key":"10.1016\/j.intimp.2021.107398_b0240","first-page":"747","article-title":"Leflunomide, a novel immunomodulatory agent: in vitro analyses of the mechanism of immunosuppression","volume":"25","author":"Chong","year":"1993","journal-title":"Transpl. Proc."},{"issue":"2","key":"10.1016\/j.intimp.2021.107398_b0245","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbrc.2018.01.107","article-title":"Leflunomide: A promising drug with good antitumor potential","volume":"496","author":"Zhang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2021.107398_b0250","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0022-3565(25)12093-4","article-title":"The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis","volume":"275","author":"Cherwinski","year":"1995","journal-title":"J. Pharmacol. Experim. Therapeut."},{"key":"10.1016\/j.intimp.2021.107398_b0255","doi-asserted-by":"crossref","unstructured":"K. Siemasko, A.S. Chong, H.M. Jack, H. Gong, J.W. Williams, A. Finnegan, Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production, J. Immunol. (Baltimore, Md : 1950) 160(4) (1998) 1581\u20131588.","DOI":"10.4049\/jimmunol.160.4.1581"},{"issue":"6","key":"10.1016\/j.intimp.2021.107398_b0260","first-page":"3079","article-title":"A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2","volume":"28","author":"Cao","year":"1996","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.intimp.2021.107398_b0265","doi-asserted-by":"crossref","DOI":"10.1007\/BF01991144","article-title":"Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers","volume":"38","author":"Zielinski","year":"1993","journal-title":"Agents Actions"},{"issue":"21","key":"10.1016\/j.intimp.2021.107398_b0270","doi-asserted-by":"crossref","first-page":"12398","DOI":"10.1074\/jbc.270.21.12398","article-title":"Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide","volume":"270","author":"Xu","year":"1995","journal-title":"J. Biolog. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2021.107398_b0275","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.coph.2011.05.003","article-title":"Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: current and emerging therapeutic options","volume":"11","author":"Pignataro","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.intimp.2021.107398_b0280","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fimmu.2012.00228","article-title":"Akt and mTOR in B Cell Activation and Differentiation","volume":"3","author":"Limon","year":"2012","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2021.107398_b0285","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.neo.2014.08.006","article-title":"Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress","volume":"16","author":"Doscas","year":"2014","journal-title":"Neoplasia (New York, NY)"},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0290","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.autrev.2004.05.001","article-title":"Mast cells and autoimmunity","volume":"4","author":"Rottem","year":"2005","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar1446","article-title":"Mast cells in inflammatory arthritis","volume":"7","author":"Nigrovic","year":"2005","journal-title":"Arthritis Res. Therapy"},{"key":"10.1016\/j.intimp.2021.107398_b0300","doi-asserted-by":"crossref","unstructured":"N. Sawamukai, K. Saito, K. Yamaoka, S. Nakayamada, C. Ra, Y. Tanaka, Leflunomide inhibits PDK1\/Akt pathway and induces apoptosis of human mast cells, J. immunol. (Baltimore, Md : 1950) 179(10) (2007) 6479\u20136484.","DOI":"10.4049\/jimmunol.179.10.6479"},{"issue":"3\u20134","key":"10.1016\/j.intimp.2021.107398_b0305","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/BF02001911","article-title":"Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation","volume":"41","author":"Weithmann","year":"1994","journal-title":"Agents Actions"},{"issue":"Suppl 2","key":"10.1016\/j.intimp.2021.107398_b0310","first-page":"S187","article-title":"Leflunomide: an active antiinflammatory and antiproliferative agent in models of dermatologic disease","volume":"44","author":"Kurtz","year":"1995","journal-title":"Inflam. Res. Off. J. European Histamine Res. Soc. [et al]"},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0315","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00296-010-1630-z","article-title":"Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice","volume":"32","author":"He","year":"2012","journal-title":"Rheumatol. Int."},{"issue":"8","key":"10.1016\/j.intimp.2021.107398_b0320","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/1529-0131(200008)43:8<1820::AID-ANR18>3.0.CO;2-D","volume":"43","author":"Kraan","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2021.107398_b0325","doi-asserted-by":"crossref","unstructured":"S.K. Manna, B.B. Aggarwal, Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression, J. Immunol. (Baltimore, Md: 1950) 162(4) (1999) 2095\u20132102.","DOI":"10.4049\/jimmunol.162.4.2095"},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0330","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12974-017-0829-2","article-title":"Teriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity","volume":"14","author":"Ambrosius","year":"2017","journal-title":"J. Neuroinflam."},{"issue":"11","key":"10.1016\/j.intimp.2021.107398_b0335","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.59.11.841","article-title":"Leflunomide: mode of action in the treatment of rheumatoid arthritis","volume":"59","author":"Breedveld","year":"2000","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0340","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejphar.2011.07.045","article-title":"Inhibiting effects of Leflunomide metabolite on overexpression of CD147, MMP-2 and MMP-9 in PMA differentiated THP-1 cells","volume":"670","author":"Huang","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107398_b0345","first-page":"641","article-title":"Effects of leflunomide on inflamation and fibrosis in bleomycine induced pulmonary fibrosis in wistar albino rats","volume":"5","author":"Kayhan","year":"2013","journal-title":"J. Thoracic Dis."},{"issue":"6","key":"10.1016\/j.intimp.2021.107398_b0350","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/ard.2005.045641","article-title":"Anti-inflammatory effects of leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients","volume":"65","author":"Cutolo","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0355","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1038\/s41467-019-12163-z","article-title":"HIF1alpha inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis","volume":"10","author":"Liang","year":"2019","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.intimp.2021.107398_b0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013128","article-title":"Tanguay RL et al.: The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor","volume":"5","author":"O'Donnell","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2021.107398_b0365","unstructured":"W.W. Cao, P.N. Kao, A.C. Chao, P. Gardner, J. Ng, R.E. Morris, Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides, J. Heart Lung Transplant.: Off. Publ. Int. Soc. Heart Transplant. 14(6 Pt 1) (1995) 1016\u20131030."},{"issue":"9","key":"10.1016\/j.intimp.2021.107398_b0370","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0006-2952(99)00228-2","article-title":"In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action","volume":"58","author":"Xu","year":"1999","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107398_b0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071555","article-title":"Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo","volume":"8","author":"Zhu","year":"2013","journal-title":"PLoS ONE"},{"issue":"18","key":"10.1016\/j.intimp.2021.107398_b0380","doi-asserted-by":"crossref","first-page":"30438","DOI":"10.18632\/oncotarget.16737","article-title":"Inhibition of p70 S6 kinase (S6K1) activity by A77 1726, the active metabolite of leflunomide, induces autophagy through TAK1-mediated AMPK and JNK activation","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2021.107398_b0385","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.omto.2019.04.006","article-title":"Leflunomide synergizes with gemcitabine in growth inhibition of PC cells and impairs c-Myc signaling through PIM kinase targeting","volume":"14","author":"Buettner","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"issue":"7","key":"10.1016\/j.intimp.2021.107398_b0390","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/bloodadvances.2018027227","article-title":"Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting","volume":"3","author":"Buettner","year":"2019","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.intimp.2021.107398_b0395","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0006-2952(96)00303-6","article-title":"Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation","volume":"52","author":"Xu","year":"1996","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0400","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41598-018-19788-y","article-title":"Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1\/EphA2 system in bladder cancer","volume":"8","author":"Chu","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0405","first-page":"223","article-title":"Leflunomide inhibits cytokine-induced DNA synthesis of rabbit synovial cells in culture","volume":"15","author":"Ju","year":"1994","journal-title":"Zhongguo yao li xue bao = Acta Pharmacol. Sin."},{"issue":"2","key":"10.1016\/j.intimp.2021.107398_b0410","first-page":"90","article-title":"[Leflunomide inhibits PAF induced DNA synthesis in rabbit synovial cells and PAF production from rat peritoneal macrophages]","volume":"29","author":"Ju","year":"1994","journal-title":"Yao xue xue bao = Acta Pharm. Sin."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0415","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0022-3565(25)24292-6","article-title":"The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism","volume":"272","author":"Cherwinski","year":"1995","journal-title":"J. Pharmacol. Experim. Therapeut."},{"issue":"2","key":"10.1016\/j.intimp.2021.107398_b0420","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1399-3062.2011.00682.x","article-title":"Leflunomide for cytomegalovirus: bench to bedside","volume":"14","author":"Chacko","year":"2012","journal-title":"Transplant Infect. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0425","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.humimm.2004.12.005","article-title":"CMV-infected allogeneic endothelial cells initiate responder and bystander donor HLA class I release via the metalloproteinase cleavage pathway","volume":"66","author":"Haynes","year":"2005","journal-title":"Hum. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0430","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/01.TP.0000137334.46155.94","article-title":"Mechanistic study of malononitrileamide FK778 in cardiac transplantation and CMV infection in rats","volume":"79","author":"Zeng","year":"2005","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0435","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3851\/IMP1763","article-title":"Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide","volume":"16","author":"Dunn","year":"2011","journal-title":"Antiviral Therapy"},{"issue":"10","key":"10.1016\/j.intimp.2021.107398_b0440","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1007\/s00415-020-09944-8","article-title":"COVID-19 in teriflunomide-treated patients with multiple sclerosis","volume":"267","author":"Maghzi","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2021.107398_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111681","article-title":"Dihydroorotate dehydrogenase inhibitors in anti-infective drug research","volume":"183","author":"Boschi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2021.107398_b0450","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0149-2918(04)90048-3","article-title":"Leflunomide in the treatment of rheumatoid arthritis","volume":"26","author":"Li","year":"2004","journal-title":"Clin. Ther."},{"issue":"12","key":"10.1016\/j.intimp.2021.107398_b0455","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1001\/archdermatol.2008.502","article-title":"Is leflunomide effective in the treatment of psoriasis in a patient who is unable to benefit from standard first- and second-line therapies and needs an affordable treatment option?","volume":"144","author":"Affleck","year":"2008","journal-title":"Arch. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2021.107398_b0460","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2165\/00003495-199958060-00010","article-title":"Leflunomide: a review of its use in active rheumatoid arthritis","volume":"58","author":"Prakash","year":"1999","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.intimp.2021.107398_b0465","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1191\/0961203304lu1067sr","article-title":"Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus","volume":"13","author":"Tam","year":"2004","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.intimp.2021.107398_b0470","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/acr.22035","article-title":"Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review","volume":"65","author":"Pego-Reigosa","year":"2013","journal-title":"Arthritis Care Res."},{"issue":"6","key":"10.1016\/j.intimp.2021.107398_b0475","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2174\/1570159X14666161208151525","article-title":"From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis","volume":"15","author":"Aly","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.intimp.2021.107398_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2014.06.005","article-title":"Teriflunomide (Aubagio\u00ae) for the treatment of multiple sclerosis","author":"Bar-Or","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.intimp.2021.107398_b0485","unstructured":"sanofi-aventis: Teriflunomide (AUBAGIO). Multiple sclerosis: just a metabolite of leflunomide. Prescrire Int. 24(158) (2015) 61\u201364."},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0490","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.berh.2006.03.003","article-title":"Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy","volume":"20","author":"Akkoc","year":"2006","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0495","first-page":"445","volume":"27","author":"Morris","year":"1995","journal-title":"Transpl. Proc."},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0500","first-page":"1263","article-title":"Effect of leflunomide in control of acute rejection in hamster-to-rat cardiac xenografts","volume":"26","author":"Xiao","year":"1994","journal-title":"Transpl. Proc."},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0505","first-page":"1599","article-title":"Leflunomide immunosuppression in rat small intestinal transplantation","volume":"26","author":"Foster","year":"1994","journal-title":"Transpl. Proc."},{"issue":"12","key":"10.1016\/j.intimp.2021.107398_b0510","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1097\/00007890-199457120-00005","article-title":"An evaluation of leflunomide in the canine renal transplantation model","volume":"57","author":"McChesney","year":"1994","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.intimp.2021.107398_b0515","first-page":"3783","article-title":"Promotion of corneal allograft survival with leflunomide","volume":"35","author":"Niederkorn","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0520","first-page":"1310","article-title":"Leflunomide and cyclosporin-A prolong fish-to-mouse islet xenograft survival in BALB\/C mice","volume":"26","author":"Wright","year":"1994","journal-title":"Transpl. Proc."},{"issue":"2","key":"10.1016\/j.intimp.2021.107398_b0525","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41409-019-0545-x","article-title":"Leflunomide for chronic musculoskeletal graft versus host disease following allogeneic hematopoietic stem cell transplant","volume":"55","author":"Punatar","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"8","key":"10.1016\/j.intimp.2021.107398_b0530","first-page":"317","article-title":"Leflunomide interferes with pyrimidine nucleotide biosynthesis","volume":"44","author":"Cherwinski","year":"1995","journal-title":"Inflam. Res. Off. J. Eur. Histamine Res. Soc. et al]"},{"key":"10.1016\/j.intimp.2021.107398_b0535","unstructured":"M.H. Mabry, Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer. In.: https:\/\/ClinicalTrials.gov\/show\/NCT00004071, 2007."},{"key":"10.1016\/j.intimp.2021.107398_b0540","unstructured":"Pfizer: SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme. In.: https:\/\/ClinicalTrials.gov\/show\/NCT00003293, 1998."},{"key":"10.1016\/j.intimp.2021.107398_b0545","unstructured":"M.A. Rosenzweig, Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma. In.: https:\/\/ClinicalTrials.gov\/show\/NCT04370483. June 2020, 2020b."},{"key":"10.1016\/j.intimp.2021.107398_b0550","first-page":"1","article-title":"Repurposing leflunomide for relapsed\/refractory multiple myeloma: a phase 1 study","author":"Rosenzweig","year":"2020","journal-title":"Leukemia Lymphoma"},{"issue":"41","key":"10.1016\/j.intimp.2021.107398_b0555","doi-asserted-by":"crossref","first-page":"69906","DOI":"10.18632\/oncotarget.19436","article-title":"Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells","volume":"8","author":"Imanishi","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0560","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cell.2016.08.057","article-title":"Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia","volume":"167","author":"Sykes","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2021.107398_b0565","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.msard.2017.07.001","article-title":"A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis","volume":"17","author":"Landais","year":"2017","journal-title":"Multiple Sclerosis Related Dis."},{"key":"10.1016\/j.intimp.2021.107398_b0570","unstructured":"A. Muehler, N. Ahuja, A study to evaluate the efficacy, safety and tolerability of IMU-838 as addition to investigator's choice of standard of care therapy, in Patients With Coronavirus Disease 19 (COVID-19). clinicaltrial.gov: https:\/\/ClinicalTrials.gov\/show\/NCT04379271, 2020."},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0575","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrrheum.2010.214","article-title":"Hepatotoxicity related to antirheumatic drugs","volume":"7","author":"Aithal","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0973-3698(11)60043-5","article-title":"Monitoring adverse effects of leflunomide: role of clinical audit","volume":"6","author":"Subramanian","year":"2011","journal-title":"Indian J. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0585","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00006416-200301000-00013","article-title":"Rheumatoid arthritis and the Arava (leflunomide) controversy","volume":"22","author":"Turkoski","year":"2003","journal-title":"Orthopedic Nursing"},{"key":"10.1016\/j.intimp.2021.107398_b0590","unstructured":"EMEA: EMEA Public Statement On Leflunomide (ARAVA)-Severe And Serious Hepatic Reactions-24 Oct 2020, in: EMEA, 2001."},{"key":"10.1016\/j.intimp.2021.107398_b0595","unstructured":"publiccitizin: Arava Linked to Liver Complications and Deaths, Public Citizen Tells FDA. In.; 2002."},{"issue":"7342","key":"10.1016\/j.intimp.2021.107398_b0600","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/bmj.324.7342.869\/a","article-title":"Arthritis drug should be removed from market, says consumer group","volume":"324","author":"Charatan","year":"2002","journal-title":"BMJ (Clin. Res. ed)"},{"issue":"2","key":"10.1016\/j.intimp.2021.107398_b0605","doi-asserted-by":"crossref","first-page":"100","DOI":"10.47102\/annals-acadmedsg.V36N2p100","article-title":"Outcomes of chronic hepatitis B infection in Oriental patients with rheumatic diseases","volume":"36","author":"Thong","year":"2007","journal-title":"Ann. Acad. Med. Singapore"},{"issue":"8","key":"10.1016\/j.intimp.2021.107398_b0610","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3748\/wjg.v18.i8.821","article-title":"Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis","volume":"18","author":"Zheng","year":"2012","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107398_b0615","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00296-018-4189-8","article-title":"Cyclophosphamide-induced severe acute hepatitis in a rheumatic disease: case-based review","volume":"39","author":"\u00dcsk\u00fcdar Cansu","year":"2019","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.intimp.2021.107398_b0620","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1000-1948(10)60020-2","article-title":"Leflunomide-induced acute liver failure: a case report","volume":"25","author":"Yuyuan","year":"2010","journal-title":"J. Med. Colleges PLA"},{"issue":"2","key":"10.1016\/j.intimp.2021.107398_b0625","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3748\/wjg.v9.i2.320","article-title":"Effect of leflunomide on immunological liver injury in mice","volume":"9","author":"Yao","year":"2003","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107398_b0630","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1590\/S0482-50042011000200004","article-title":"Liver toxicity is rare in rheumatoid arthritis patients using combination therapy with leflunomide and methotrexate","volume":"51","author":"Alves","year":"2011","journal-title":"Revista brasileira de reumatologia"},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0635","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pharep.2014.08.009","article-title":"Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritis","volume":"67","author":"Bilasy","year":"2015","journal-title":"Pharmacolog. Rep. PR"},{"issue":"6","key":"10.1016\/j.intimp.2021.107398_b0640","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd1750","article-title":"Idiosyncratic drug hepatotoxicity","volume":"4","author":"Kaplowitz","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2021.107398_b0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116824","article-title":"Leflunomide-induced liver injury in mice: Involvement of TLR4 mediated activation of PI3K\/mTOR\/NF\u03baB pathway","volume":"235","author":"Elshaer","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2021.107398_b0650","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tox.2017.10.002","article-title":"Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells","volume":"392","author":"Ren","year":"2017","journal-title":"Toxicology"},{"key":"10.1016\/j.intimp.2021.107398_b0655","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tox.2018.02.003","article-title":"Mitochondrial dysfunction induced by leflunomide and its active metabolite","volume":"396\u2013397","author":"Xuan","year":"2018","journal-title":"Toxicology"},{"key":"10.1016\/j.intimp.2021.107398_b0660","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.5897\/AJPP2013.3517","article-title":"Evaluation of mechanism of hepatotoxicity of leflunomide using albino wistar rats","volume":"7","author":"Lodhi","year":"2013","journal-title":"African J. Pharm. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0665","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1567-7249(02)00045-4","article-title":"Mechanism of leflunomide-induced proliferation of mitochondria in mammalian cells","volume":"2","author":"Spodnik","year":"2002","journal-title":"Mitochondrion"},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0670","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.taap.2006.08.001","article-title":"Leflunomide or A77 1726 protect from acetaminophen-induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes","volume":"217","author":"Latchoumycandane","year":"2006","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107398_b0675","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/hep.20438","article-title":"Leflunomide protects from T-cell-mediated liver injury in mice through inhibition of nuclear factor kappaB","volume":"40","author":"Imose","year":"2004","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"23","key":"10.1016\/j.intimp.2021.107398_b0680","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.3748\/wjg.15.2817","article-title":"Drug-induced liver injury: is it somehow foreseeable?","volume":"15","author":"Tarantino","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2021.107398_b0685","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00228-008-0498-2","article-title":"Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients","volume":"64","author":"Bohanec Grabar","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107398_b0690","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0002-9343(02)01177-4","article-title":"Fatal hepatitis with leflunomide and itraconazole","volume":"113","author":"Legras","year":"2002","journal-title":"Am. J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2021.107398_b0695","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.apjtm.2015.09.011","article-title":"Effect of Rheum palmatum L. on NF-kappaB signaling pathway of mice with acute liver failure","volume":"8","author":"Zhang","year":"2015","journal-title":"Asian Pac J. Trop Med."},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0700","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5455\/ajvs.212142","article-title":"Hepatoprotective Effect of Silymarin and Propolis in Chemically Induced Chronic Liver Injury in Rats","volume":"49","author":"Hashem","year":"2016","journal-title":"Alexandria J. Veterinary Sci."},{"key":"10.1016\/j.intimp.2021.107398_b0705","doi-asserted-by":"crossref","unstructured":"S.M.A. El-Sheikh, Abd El-Alim AE-AF, A.A.A. Galal, R.G. El-Sayed, N.I. El-naseery, Anti-arthritic effect of \u03b2-caryophyllene and its ameliorative role on methotrexate and\/or leflunomide-induced side effects in arthritic rats. Life Sci. 233 (2019) 116750.","DOI":"10.1016\/j.lfs.2019.116750"},{"key":"10.1016\/j.intimp.2021.107398_b0710","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jep.2016.03.024","article-title":"The protective effect of total phenolics from Oenanthe Javanica on acute liver failure induced by D-galactosamine","volume":"186","author":"Ai","year":"2016","journal-title":"J. Ethnopharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2021.107398_b0715","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165638","article-title":"AMPK activation prevents and reverses drug-induced mitochondrial and hepatocyte injury by promoting mitochondrial fusion and function","volume":"11","author":"Kang","year":"2016","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.intimp.2021.107398_b0720","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s40618-015-0287-6","article-title":"1,25(OH)2D3 downregulates the Toll-like receptor 4-mediated inflammatory pathway and ameliorates liver injury in diabetic rats","volume":"38","author":"Wang","year":"2015","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.intimp.2021.107398_b0725","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jep.2016.01.020","article-title":"Aqueous extract from Aconitum carmichaelii Debeaux reduces liver injury in rats via regulation of HMGB1\/TLR4\/NF-KappaB\/caspase-3 and PCNA signaling pathways","volume":"183","author":"Luo","year":"2016","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.intimp.2021.107398_b0730","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.2147\/DDDT.S207226","article-title":"Efficacy and safety of total glucosides of paeony combined with methotrexate and leflunomide for active rheumatoid arthritis: a meta-analysis","volume":"13","author":"Huang","year":"2019","journal-title":"Drug Des. Develop. Therapy"},{"key":"10.1016\/j.intimp.2021.107398_b0735","doi-asserted-by":"crossref","first-page":"8292486","DOI":"10.1155\/2016\/8292486","article-title":"Assessment of the therapeutic effect of total glucosides of peony for juvenile idiopathic arthritis: a systematic review and meta-analysis","volume":"2016","author":"Cai","year":"2016","journal-title":"Evid. Based Complement. Alternative Med. eCAM"},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0740","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0090-1229(06)80011-5","article-title":"Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats","volume":"61","author":"Ogawa","year":"1991","journal-title":"Clin. Immunol. Immunopathol."},{"issue":"3\u20134","key":"10.1016\/j.intimp.2021.107398_b0745","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/BF01966492","article-title":"The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery","volume":"21","author":"Popovic","year":"1987","journal-title":"Agents Actions"},{"issue":"9","key":"10.1016\/j.intimp.2021.107398_b0750","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0192-0561(98)00051-4","article-title":"Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction","volume":"20","author":"Hoskin","year":"1998","journal-title":"Int. J. Immunopharmacol."},{"issue":"34","key":"10.1016\/j.intimp.2021.107398_b0755","doi-asserted-by":"crossref","first-page":"21682","DOI":"10.1074\/jbc.273.34.21682","article-title":"Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans","volume":"273","author":"R\u00fcckemann","year":"1998","journal-title":"J. Biolog. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0760","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1365-2222.1998.00240.x","article-title":"Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma","volume":"28","author":"Eber","year":"1998","journal-title":"Clin. Experim. Allergy J. British Soc. Allergy Clin. Immunol."},{"issue":"1 Pt 2","key":"10.1016\/j.intimp.2021.107398_b0765","first-page":"1083","article-title":"Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent","volume":"23","author":"K\u00fcchle","year":"1991","journal-title":"Transpl. Proc."},{"issue":"1 Pt 1","key":"10.1016\/j.intimp.2021.107398_b0770","first-page":"763","article-title":"Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative","volume":"25","author":"Schorlemmer","year":"1993","journal-title":"Transpl. Proc."},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0775","first-page":"1613","article-title":"Oral leflunomide prevents small bowel allograft rejection in the rat","volume":"26","author":"He","year":"1994","journal-title":"Transpl. Proc."},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0780","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/xen.12238","article-title":"As2 O3 combined with leflunomide prolongs heart xenograft survival via suppressing the response of Th1, Th2, and B cells in a rat model","volume":"23","author":"Jiao","year":"2016","journal-title":"Xenotransplantation"},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0785","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trim.2012.04.001","article-title":"Combined use of rapamycin and leflunomide in prevention of acute cardiac allografts rejection in rats","volume":"27","author":"Sun","year":"2012","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.intimp.2021.107398_b0790","doi-asserted-by":"crossref","unstructured":"R.T. Elder, X. Xu, J.W. Williams, H. Gong, A. Finnegan, A.S. Chong, The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms, J. immunol. (Baltimore, Md: 1950) 159(1) (1997) 22\u201327.","DOI":"10.4049\/jimmunol.159.1.22"},{"issue":"3\u20134","key":"10.1016\/j.intimp.2021.107398_b0795","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.reprotox.2007.05.006","article-title":"Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice","volume":"24","author":"Fukushima","year":"2007","journal-title":"Reprod. Toxicol. (Elmsford, NY)"},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0800","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0022-3565(24)36813-2","article-title":"Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and -2: comparison with nonsteroidal anti-inflammatory drugs","volume":"282","author":"Curnock","year":"1997","journal-title":"J. Pharmacol. Experim. Therapeut."},{"key":"10.1016\/j.intimp.2021.107398_b0805","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.lfs.2015.10.003","article-title":"Chemopreventive effect of leflunomide against Ehrlich's solid tumor grown in mice: effect on EGF and EGFR expression and tumor proliferation","volume":"141","author":"Bahr","year":"2015","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2021.107398_b0810","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3389\/fphar.2018.00993","article-title":"Teriflunomide Is an Indirect Human Constitutive Androstane Receptor (CAR) Activator Interacting With Epidermal Growth Factor (EGF) Signaling","volume":"9","author":"Carazo","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"31","key":"10.1016\/j.intimp.2021.107398_b0815","doi-asserted-by":"crossref","first-page":"50401","DOI":"10.18632\/oncotarget.10409","article-title":"Inhibition of canonical WNT\/\u03b2-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"27","key":"10.1016\/j.intimp.2021.107398_b0820","doi-asserted-by":"crossref","first-page":"44266","DOI":"10.18632\/oncotarget.17863","article-title":"Leflunomide\/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication","volume":"8","author":"Bilger","year":"2017","journal-title":"Oncotarget"},{"issue":"5\u20136","key":"10.1016\/j.intimp.2021.107398_b0825","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000053979","article-title":"Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide","volume":"42","author":"Waldman","year":"1999","journal-title":"Intervirology"},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0830","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00007890-200101150-00031","article-title":"Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide","volume":"71","author":"Knight","year":"2001","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.intimp.2021.107398_b0835","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011937","article-title":"The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants","volume":"5","author":"Read","year":"2010","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.intimp.2021.107398_b0840","doi-asserted-by":"crossref","first-page":"34","DOI":"10.15171\/jnp.2016.06","article-title":"Evaluation of leflunomide for the treatment of BK viremia and biopsy proven BK nephropathy; a single center experience","volume":"5","author":"Nesselhauf","year":"2016","journal-title":"J. Nephropathol."},{"key":"10.1016\/j.intimp.2021.107398_b0845","unstructured":"L. Wennberg, B.K. Viremia, After Renal Transplantation: Screening, Early Diagnosis, Early Reduction in Immunosuppression and Treatment With Leflunomide (Arava), https:\/\/ClinicalTrials.gov\/show\/NCT00684372. June 2020, 2009."},{"key":"10.1016\/j.intimp.2021.107398_b0850","unstructured":"K. Flaherty, Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma. https:\/\/ClinicalTrials.gov\/show\/NCT01611675. June 2020, 2017."},{"key":"10.1016\/j.intimp.2021.107398_b0855","unstructured":"C.L. Shapiro, Leflunomide in Previously Treated Metastatic Triple Negative Cancers https:\/\/ClinicalTrials.gov\/show\/NCT03709446. June 2020, 2021."},{"key":"10.1016\/j.intimp.2021.107398_b0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2020.01.010","article-title":"Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: a randomized clinical trial","author":"Wang","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2021.107398_b0865","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s10067-018-4348-z","article-title":"Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial","volume":"38","author":"Zhang","year":"2019","journal-title":"Clin. Rheumatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921000345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921000345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:26:08Z","timestamp":1761585968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921000345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":173,"alternative-id":["S1567576921000345"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107398","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107398"}}